The size of the European Histone Deacetylase Inhibitors market is forecasted to hike at a prominent CAGR between 2021 to 2026.
HDAC is an anticancer agent. It consists of a group of molecules. Chemically speaking, these are basically enzymes with N-acetyl lysine amino acid present on a histone. They have a large number of applications in oncology. They are also used in the treatment of solid and hematological malignancies.
An increasing number of people affected by cancer, better funding and savory government policies for R&D in the cancer treatment field, and high demand for efficient treatment with lower costs are the primary drivers of market growth. Ambiguity in the reimbursement policies is the primary restraint of this market. The market is segmented by class and application. Classification by class entails Class I HDACs, Class II HDACs, and Class III HDACs. Classification by application entails Cancer, Central Nervous System Disorders, and Other Diseases.
Classification by geography entails UK, Spain, Germany, France, and others. Europe comes second with market share. It is, however, anticipated to experience slow growth in the forecast period. The UK will lead the market in Europe.
Key players in the market are Merck & Co., Inc., Celgene Corporation, Eisai Pharmaceuticals. Other players in the market include Novartis, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals, and Pfizer, Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Class
5.1.1 Introduction
5.1.2 Class I HDACs
5.1.3 Class II HDACs
5.1.4 Class III HDACs
5.1.5 Y-o-Y Growth Analysis, By Class
5.1.6 Market Attractiveness Analysis, By Class
5.1.7 Market Share Analysis, By Class
5.2 Application
5.2.1 Introduction
5.2.2 Cancer
5.2.3 Central Nervous System Disorders
5.2.4 Other Diseases
5.2.5 Y-o-Y Growth Analysis, By Application
5.2.6 Market Attractiveness Analysis, By Application
5.2.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Class
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Class
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Class
6.1.5.3 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Celgene
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Acetylon Pharmaceuticals
8.3 Celleron Therapeutics
8.4 Envivo Pharmaceuticals
8.5 Novartis
8.6 Merck & Co.
8.7 Pfizer
8.8 Eisai Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
